Medicine:IIBR-100
From HandWiki
Short description: Vaccine candidate against COVID-19
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | viral |
| Clinical data | |
| Other names | Brilife |
| Routes of administration | Intramuscular |
IIBR-100 also known as Brilife is a COVID-19 vaccine candidate developed by The Israel Institute for Biological Research.[1][2]
References
- ↑ Clinical trial number NCT04608305 for "Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults" at ClinicalTrials.gov
- ↑ "As Israel goes vaccine-wild, will the homegrown version lose its shot?". 29 December 2020. https://www.timesofisrael.com/as-israel-goes-vaccine-wild-will-the-homegrown-version-lose-its-shot/.
External links
 |
